MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3
- 1 February 2017
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 386, 168-178
Abstract
No abstract availableKeywords
Funding Information
- Korean government (NRF-2015-R1A2A2A01005197, KHIDI-HI16C1559)
This publication has 33 references indexed in Scilit:
- Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell FrequencyClinical Cancer Research, 2015
- Notch3 functions as a regulator of cell self-renewal by interacting with the β-catenin pathway in hepatocellular carcinomaOncotarget, 2015
- Targeting Notch signaling pathway in cancer: Clinical development advances and challengesPharmacology & Therapeutics, 2014
- Prognostic significance of Notch 3 gene expression in ovarian serous carcinomaCancer Science, 2010
- Jagged-1 and Notch3 Juxtacrine Loop Regulates Ovarian Tumor Growth and AdhesionCancer Research, 2008
- Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2007
- Notch3Gene Amplification in Ovarian CancerCancer Research, 2006
- Oncomirs — microRNAs with a role in cancerNature Reviews Cancer, 2006
- Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA TargetsCell, 2005
- Cancer of the OvaryNew England Journal of Medicine, 2004